Stock events for Zenas BioPharma, Inc. (ZBIO)
ZBIO reached its 52-week high on December 24, 2025. Positive results from the Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease were announced on January 5, 2026. The company announced a late-breaking platform presentation of results from the Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at the ACTRIMS Forum 2026 on February 9, 2026. In early March 2026, the stock price experienced fluctuations around its 50-day and 15-day moving averages. As of March 7, 2026, ZBIO had an AI Score of 6/10 (Hold) from Danelfin. Shareholder investigations by Purcell & Lefkowitz LLP were announced on February 17, 2026, and January 5, 2026.
Demand Seasonality affecting Zenas BioPharma, Inc.’s stock price
Information regarding demand seasonality for Zenas BioPharma, Inc.'s products and services was not available in the provided search results. Demand for its pipeline products, once approved, would likely be driven by disease prevalence and treatment efficacy rather than typical seasonal patterns.
Overview of Zenas BioPharma, Inc.’s business
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing and commercializing therapies for autoimmune and rare diseases. The company's lead product candidate is obexelimab, a bifunctional monoclonal antibody being developed for indications such as immunoglobulin G4-related disease, relapsing multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Other programs in the company's pipeline include Orelabrutinib, ZB002, ZB004, ZB001, ZB005, a preclinical oral IL-17AA/AF inhibitor, and a preclinical oral, brain-penetrant, TYK2 inhibitor.
ZBIO’s Geographic footprint
Zenas BioPharma, Inc. serves a global patient population and collaborates with healthcare professionals worldwide. The company is headquartered in Waltham, Massachusetts, United States.
ZBIO Corporate Image Assessment
Specific events directly impacting Zenas BioPharma, Inc.'s brand reputation in the past year were not extensively detailed in the provided search results. Positive clinical trial results for obexelimab are generally positive, while shareholder investigations could potentially have a negative impact.
Ownership
Information regarding major institutional and individual owners of Zenas BioPharma, Inc. was not explicitly detailed in the provided search results. GuruFocus identified "Fairmount Healthcare Fund Ii L.p." in connection with Zenas BioPharma Inc Executives. Simply Wall St provides a "View Ownership" section for Zenas BioPharma, Inc.
